Literature DB >> 31216476

The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma.

Bengt Phung1, Maciej Cieśla2, Adriana Sanna1, Nicola Guzzi2, Giulia Beneventi2, Phuong Cao Thi Ngoc2, Martin Lauss1, Rita Cabrita1, Eugenia Cordero3, Ana Bosch1, Frida Rosengren1, Jari Häkkinen1, Klaus Griewank4, Annette Paschen4, Katja Harbst1, Håkan Olsson1, Christian Ingvar5, Ana Carneiro6, Hensin Tsao7, Dirk Schadendorf4, Kristian Pietras3, Cristian Bellodi8, Göran Jönsson9.   

Abstract

The X-linked DDX3X gene encodes an ATP-dependent DEAD-box RNA helicase frequently altered in various human cancers, including melanomas. Despite its important roles in translation and splicing, how DDX3X dysfunction specifically rewires gene expression in melanoma remains completely unknown. Here, we uncover a DDX3X-driven post-transcriptional program that dictates melanoma phenotype and poor disease prognosis. Through an unbiased analysis of translating ribosomes, we identified the microphthalmia-associated transcription factor, MITF, as a key DDX3X translational target that directs a proliferative-to-metastatic phenotypic switch in melanoma cells. Mechanistically, DDX3X controls MITF mRNA translation via an internal ribosome entry site (IRES) embedded within the 5' UTR. Through this exquisite translation-based regulatory mechanism, DDX3X steers MITF protein levels dictating melanoma metastatic potential in vivo and response to targeted therapy. Together, these findings unravel a post-transcriptional layer of gene regulation that may provide a unique therapeutic vulnerability in aggressive male melanomas.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DDX3X; IRES; MITF; melanocyte; melanoma; metastasis; migration; resistance; therapy; translation control

Year:  2019        PMID: 31216476     DOI: 10.1016/j.celrep.2019.05.069

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  26 in total

Review 1.  Sex disparities matter in cancer development and therapy.

Authors:  Sue Haupt; Franco Caramia; Sabra L Klein; Joshua B Rubin; Ygal Haupt
Journal:  Nat Rev Cancer       Date:  2021-04-20       Impact factor: 60.716

2.  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development.

Authors:  Ashley L Lennox; Mariah L Hoye; Ruiji Jiang; Bethany L Johnson-Kerner; Lindsey A Suit; Srivats Venkataramanan; Charles J Sheehan; Fernando C Alsina; Brieana Fregeau; Kimberly A Aldinger; Ching Moey; Iryna Lobach; Alexandra Afenjar; Dusica Babovic-Vuksanovic; Stéphane Bézieau; Patrick R Blackburn; Jens Bunt; Lydie Burglen; Philippe M Campeau; Perrine Charles; Brian H Y Chung; Benjamin Cogné; Cynthia Curry; Maria Daniela D'Agostino; Nataliya Di Donato; Laurence Faivre; Delphine Héron; A Micheil Innes; Bertrand Isidor; Boris Keren; Amy Kimball; Eric W Klee; Paul Kuentz; Sébastien Küry; Dominique Martin-Coignard; Ghayda Mirzaa; Cyril Mignot; Noriko Miyake; Naomichi Matsumoto; Atsushi Fujita; Caroline Nava; Mathilde Nizon; Diana Rodriguez; Lot Snijders Blok; Christel Thauvin-Robinet; Julien Thevenon; Marie Vincent; Alban Ziegler; William Dobyns; Linda J Richards; A James Barkovich; Stephen N Floor; Debra L Silver; Elliott H Sherr
Journal:  Neuron       Date:  2020-03-04       Impact factor: 17.173

3.  Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma.

Authors:  Rached Alkallas; Mathieu Lajoie; Dan Moldoveanu; Karen Vo Hoang; Philippe Lefrançois; Marine Lingrand; Mozhdeh Ahanfeshar-Adams; Kevin Watters; Alan Spatz; Jonathan H Zippin; Hamed S Najafabadi; Ian R Watson
Journal:  Nat Cancer       Date:  2020-06-22

Review 4.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

5.  Sexually dimorphic RNA helicases DDX3X and DDX3Y differentially regulate RNA metabolism through phase separation.

Authors:  Hui Shen; Amber Yanas; Michael C Owens; Celia Zhang; Clark Fritsch; Charlotte M Fare; Katie E Copley; James Shorter; Yale E Goldman; Kathy Fange Liu
Journal:  Mol Cell       Date:  2022-05-18       Impact factor: 19.328

Review 6.  The plasticity of mRNA translation during cancer progression and therapy resistance.

Authors:  Lucilla Fabbri; Alina Chakraborty; Caroline Robert; Stéphan Vagner
Journal:  Nat Rev Cancer       Date:  2021-08-02       Impact factor: 60.716

Review 7.  Ribosome Biogenesis and Cancer: Overview on Ribosomal Proteins.

Authors:  Annalisa Pecoraro; Martina Pagano; Giulia Russo; Annapina Russo
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

8.  The small Cajal body-specific RNA 15 (SCARNA15) directs p53 and redox homeostasis via selective splicing in cancer cells.

Authors:  Giulia Beneventi; Roberto Munita; Phuong Cao Thi Ngoc; Magdalena Madej; Maciej Cieśla; Sowndarya Muthukumar; Nicolai Krogh; Henrik Nielsen; Vinay Swaminathan; Cristian Bellodi
Journal:  NAR Cancer       Date:  2021-07-09

9.  Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.

Authors:  Abdullah Al Emran; Jérémie Nsengimana; Gaya Punnia-Moorthy; Ulf Schmitz; Stuart J Gallagher; Julia Newton-Bishop; Jessamy C Tiffen; Peter Hersey
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

10.  Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms.

Authors:  Joe Taylor; Alison M Yeomans; Graham Packham
Journal:  Explor Target Antitumor Ther       Date:  2020-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.